Acurx Announces Presentation and Update of Its pol IIIC R&D

Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted...

Related Keywords

Philadelphia , Pennsylvania , United States , America , Robertj Deluccia , , Data Monitoring Committee , Company Ph , Nasdaq , Society Or Healthcare Epidemiology Of America , Acurx Pharmaceuticals Inc , Exchange Commission , Trial Oversight Committee , World Antimicrobial Resistance Congress , Exchange Commission On Form , Drug Administration , Acurx Pharmaceuticals , Prnewswire Acurx Pharmaceuticals Inc , World Antimicrobial Resistance Scientific Congress On , Infectious Diseases Society Of America , Interim Analysis , Independent Data Monitoring , Lead Optimization , Acute Bacterial Skin , Skin Structure Infections , Acurx Executive Chairman , Innovation Showcase , Independent Data Monitoring Committee , Gram Positive Selective Spectrum , Investigational New Drug Application , Qualified Infectious Disease Product , Generating New Antibiotic Incentives Now , World Antimicrobial Resistance , Antimicrobial Resistance , Clinical Practice Guidelines , Infectious Diseases Society , Healthcare Epidemiology , New England Journal , Bile Acid , Ibezapolstat Phase , Scientific Advisory Board , Private Securities Litigation Reform Act , Nc ,